|
10 Sep 2025 |
Granules
|
Consensus Share Price Target
|
525.10 |
573.71 |
- |
9.26 |
buy
|
|
|
|
|
06 Jun 2025
|
Granules
|
Geojit BNP Paribas
|
525.10
|
599.00
|
529.95
(-0.92%)
|
14.07 |
Accumulate
|
|
|
Validation activities have begun in Phase 2, Genome Valley, in this quarter. Also, the company continues to invest in research and development efforts aimed at building a pipeline of high-value molecules, with a focus on backward integration, especially in the oncology and CNS segment. The company has filed its first oncology molecule in this quarter....
|
|
28 May 2025
|
Granules
|
Motilal Oswal
|
525.10
|
600.00
|
522.40
(0.52%)
|
14.26 |
Buy
|
|
|
Granules India (GRAN) delivered a slightly better-than-expected revenue in 4QFY25. However, it reported largely in-line EBITDA/PAT for the quarter.
|
|
17 Feb 2025
|
Granules
|
Geojit BNP Paribas
|
525.10
|
580.00
|
522.25
(0.55%)
|
10.46 |
Accumulate
|
|
|
|
|
25 Jan 2025
|
Granules
|
Motilal Oswal
|
525.10
|
665.00
|
582.00
(-9.78%)
|
26.64 |
Buy
|
|
|
Granules India (GRAN) delivered better-than-expected revenue, while EBITDA/PAT stood in line for the quarter. The traction in finished dosage (FDF) remained robust for six quarters now.
|
|
06 Nov 2024
|
Granules
|
Sharekhan
|
525.10
|
700.00
|
576.45
(-8.91%)
|
33.31 |
Buy
|
|
|
Revenues stood at Rs. 957 crore, falling 19% y-o-y and 18% q-o-q, falling 5% short of our estimates.
|
|
12 Sep 2024
|
Granules
|
Motilal Oswal
|
525.10
|
680.00
|
564.90
(-7.05%)
|
Target met |
Buy
|
|
|
Granules India (GRAN) was issued a Form 483 with six observations for its Gagillapur site after a recent USFDA inspection.
|
|
16 Aug 2024
|
Granules
|
Geojit BNP Paribas
|
525.10
|
732.00
|
662.35
(-20.72%)
|
|
Accumulate
|
|
|
|
|
31 Jul 2024
|
Granules
|
Motilal Oswal
|
525.10
|
680.00
|
630.10
(-16.66%)
|
Target met |
Buy
|
|
|
Granules India (GRAN) posted in-line revenue in 1QFY25. However, it delivered better-than-estimated 1QFY25 EBITDA/PAT led by the increased share of formulation sales.
|
|
31 Jul 2024
|
Granules
|
ICICI Direct
|
525.10
|
765.00
|
630.10
(-16.66%)
|
|
Buy
|
|
|
|
|
26 Jun 2024
|
Granules
|
Sharekhan
|
525.10
|
600.00
|
502.20
(4.56%)
|
Target met |
Buy
|
|
|
We reiterate a Buy on Granules as the company is focusing on value-added products to increase its EBITDA margins to 22% plus from 19% in FY24.
|
|
05 Jun 2024
|
Granules
|
Geojit BNP Paribas
|
525.10
|
470.00
|
440.65
(19.16%)
|
Target met |
Accumulate
|
|
|
|
|
03 Jun 2024
|
Granules
|
ICICI Direct
|
525.10
|
515.00
|
441.10
(19.04%)
|
Target met |
Buy
|
|
|
|
|
23 Mar 2024
|
Granules
|
Sharekhan
|
525.10
|
500.00
|
430.75
(21.90%)
|
Target met |
Buy
|
|
|
|
|
22 Mar 2024
|
Granules
|
ICICI Direct
|
525.10
|
515.00
|
430.75
(21.90%)
|
Target met |
Buy
|
|
|
|
|
01 Dec 2023
|
Granules
|
Geojit BNP Paribas
|
525.10
|
464.00
|
392.85
(33.66%)
|
Target met |
Accumulate
|
|
|
|
|
09 Aug 2023
|
Granules
|
Motilal Oswal
|
525.10
|
370.00
|
322.40
(62.87%)
|
Target met |
Buy
|
|
|
|
|
28 Jul 2023
|
Granules
|
Hem Securities
|
525.10
|
391.00
|
321.30
(63.43%)
|
Target met |
Buy
|
|
|
|
|
19 Jun 2023
|
Granules
|
ICICI Direct
|
525.10
|
360.00
|
294.75
(78.15%)
|
Target met |
Buy
|
|
|
|
|
13 Jun 2023
|
Granules
|
Geojit BNP Paribas
|
525.10
|
342.00
|
285.35
(84.02%)
|
Target met |
Buy
|
|
|
|
|
17 May 2023
|
Granules
|
ICICI Direct
|
525.10
|
360.00
|
285.95
(83.63%)
|
Target met |
Buy
|
|
|
|